{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:34:07Z","timestamp":1790447647469,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.critrevonc.2022.103801","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T20:48:00Z","timestamp":1661633280000},"page":"103801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"179","author":[{"given":"Giuseppe","family":"Fallara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Belladelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Robesti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Raggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Nocera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Marandino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Galsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Malavaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2022.103801_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2753.2010.01516.x","article-title":"Assessment of study quality for systematic reviews: a comparison of the cochrane collaboration risk of bias tool and the effective public health practice project quality assessment tool: methodological research","volume":"18","author":"Armijo-Olivo","year":"2012","journal-title":"J. Eval. Clin. Pr."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103801_bib2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.eururo.2020.04.061","article-title":"Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer from the PREVAIL trial","volume":"78","author":"Armstrong","year":"2020","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103801_bib3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103801_bib4","doi-asserted-by":"crossref","DOI":"10.1111\/and.13993","article-title":"The association between testosterone, estradiol and their ratio and mortality among US men","volume":"53","author":"Belladelli","year":"2021","journal-title":"Andrologia"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103801_bib5","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.eururo.2016.06.033","article-title":"Subsequent chemotherapy and treatment patterns after abiraterone acetate in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302","volume":"71","author":"de Bono","year":"2017","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103801_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.acvd.2019.09.006","article-title":"Heart failure and atrial tachyarrhythmia on abiraterone: a pharmacovigilance study","volume":"113","author":"Bretagne","year":"2020","journal-title":"Arch. Cardiovasc Dis."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103801_bib7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur. Urol."},{"issue":"20","key":"10.1016\/j.critrevonc.2022.103801_bib8","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMc1010187","article-title":"Incomplete testosterone suppression in prostate cancer","volume":"363","author":"Crawford","year":"2010","journal-title":"N. Engl. J. Med"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103801_bib9","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1080\/0284186X.2021.1978539","article-title":"Time on treatment with abiraterone and enzalutamide in the Patient-overview Prostate Cancer in The National Prostate Cancer Register of Sweden","volume":"60","author":"Fallara","year":"2021","journal-title":"Acta Oncol."},{"issue":"12 December","key":"10.1016\/j.critrevonc.2022.103801_bib10","first-page":"1","article-title":"Observational study on time on treatment with abiraterone and enzalutamide","volume":"15","author":"Fallara","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2022.103801_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102441","article-title":"Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis","volume":"110","author":"Fallara","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103801_bib12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.23736\/S2724-6051.20.03723-6","article-title":"Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study","volume":"73","author":"Gacci","year":"2021","journal-title":"Minerva Urol. Nephrol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103801_bib13","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clgc.2019.12.019","article-title":"Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States","volume":"18","author":"George","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103801_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Method."},{"key":"10.1016\/j.critrevonc.2022.103801_bib15","series-title":"Arterioscler Thromb Vasc Biol","first-page":"E55","article-title":"Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses","author":"Hu","year":"2019"},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103801_bib16","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103801_bib17","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","article-title":"The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer","volume":"16","author":"Iacovelli","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103801_bib18","first-page":"3","article-title":"Plasma androgen receptor copy number status at emergence of metastatic castration-resistant prostate cancer: a pooled multicohort analysis","author":"Jayaram","year":"2019","journal-title":"JCO Precis Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103801_bib19","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/jamacardio.2017.2922","article-title":"Restricted mean survival time as a measure to interpret clinical trial results","volume":"2","author":"Kim","year":"2017","journal-title":"JAMA Cardiol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103801_bib20","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.euo.2019.09.005","article-title":"Real-world outcomes of sequential androgen-receptor targeting therapies with or without interposed life-prolonging drugs in metastatic castration-resistant prostate cancer: results from the dutch castration-resistant prostate cancer registry","volume":"4","author":"Kuppen","year":"2021","journal-title":"Eur. Urol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103801_bib21","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41391-021-00326-3","article-title":"Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data","volume":"24","author":"Martini","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.critrevonc.2022.103801_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102360","article-title":"Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis","volume":"104","author":"Martini","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103801_bib23","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41391-020-0231-5","article-title":"Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial","volume":"23","author":"Martini","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.critrevonc.2022.103801_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2022.08.001","article-title":"A Plea for Economically Sustainable Evidence-based Guidelines","author":"Martini","year":"2022","journal-title":"Eur. Urol."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103801_bib25","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J. Clin. Epidemiol."},{"issue":"48","key":"10.1016\/j.critrevonc.2022.103801_bib26","doi-asserted-by":"crossref","first-page":"84572","DOI":"10.18632\/oncotarget.20028","article-title":"Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials","volume":"8","author":"Moreira","year":"2017","journal-title":"Oncotarget"},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2022.103801_bib27","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2019.37.15_suppl.5008","article-title":"Alliance A031201: a phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ\/AAP) for metastatic castration resistant prostate cancer (mCRPC)","volume":"37","author":"Morris","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103801_bib28","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1111\/ajco.13426","article-title":"Efficacy of abiraterone acetate in castration-resistant metastatic prostate cancer: a real-world data analysis","volume":"17","author":"Oyman","year":"2021","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103801_bib29","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1001\/jamaoncol.2017.2797","article-title":"Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio","volume":"3","author":"Pak","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2022.103801_bib30","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920968725","article-title":"Effectiveness of abiraterone acetate plus prednisone in chemotherapy-na\u00efve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study","volume":"12","author":"Procopio","year":"2020","journal-title":"Ther. Adv. Med Oncol."},{"issue":"312","key":"10.1016\/j.critrevonc.2022.103801_bib31","doi-asserted-by":"crossref","first-page":"312re10","DOI":"10.1126\/scitranslmed.aac9511","article-title":"Plasma AR and abiraterone-resistant prostate cancer","volume":"7","author":"Romanel","year":"2015","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.critrevonc.2022.103801_bib32","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Method."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103801_bib33","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2012","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103801_bib34","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103801_bib35","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S1470-2045(21)00402-2","article-title":"Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study","volume":"22","author":"Saad","year":"2021","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103801_bib36","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2022.103801_bib37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cct.2017.02.007","article-title":"Measuring differential treatment benefit across marker specific subgroups: the choice of outcome scale","volume":"63","author":"Satagopan","year":"2017","journal-title":"Conte Clin. Trials"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103801_bib38","doi-asserted-by":"crossref","first-page":"134","DOI":"10.6004\/jnccn.2021.0008","article-title":"NCCN Guidelines Insights: Prostate Cancer, Version 1.2021","volume":"19","author":"Schaeffer","year":"2021","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103801_bib39","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.clgc.2019.07.017","article-title":"Results of a real-world study of enzalutamide and abiraterone acetate with prednisone tolerability (REAAcT)","volume":"17","author":"Shore","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103801_bib40","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.eururo.2017.03.007","article-title":"Clinical outcomes from androgen signaling-directed therapy after treatment with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302","volume":"72","author":"Smith","year":"2017","journal-title":"Eur. Urol."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103801_bib41","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/14737140.2020.1797497","article-title":"The emerging role of PARP inhibitors in prostate cancer","volume":"20","author":"Stellato","year":"2020","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103801_bib42","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/0163278702025001006","article-title":"To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data","volume":"25","author":"Stewart","year":"2002","journal-title":"Eval. Health Prof."},{"issue":"10295","key":"10.1016\/j.critrevonc.2022.103801_bib43","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet (Lond., Engl.)"},{"issue":"22","key":"10.1016\/j.critrevonc.2022.103801_bib44","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2014.55.2208","article-title":"Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis","volume":"32","author":"Uno","year":"2014","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"0","key":"10.1016\/j.critrevonc.2022.103801_bib45","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"0","author":"W","year":"2022","journal-title":"NEJM Evid."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103801_bib46","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1177\/1536867X1801700402","article-title":"Reconstructing time-to-event data from published Kaplan-Meier curves","volume":"17","author":"Wei","year":"2017","journal-title":"Stata J."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822002256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822002256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:44:50Z","timestamp":1760903090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842822002256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":46,"alternative-id":["S1040842822002256"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103801","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103801","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103801"}}